Want news from the annual meeting of the European Society for Medical Oncology? Here is the latest news from Milan:
Bevacizumab Confirmed Beneficial For First-Line Ovarian Cancer Treatment, Oct. 12, 2010. Early findings from the phase III ICON-7 study have shown that bevacizumab added to standard, first-line chemotherapy for advanced epithelial ovarian cancer improves progression-free survival to a greater extent than does standard chemotherapy alone.
Balloon Kyphoplasty Relieves Compression Fracture Pain in Cancer Patients, Oct. 11, 2010. Balloon kyphoplasty significantly relieved the pain of vertebral compression fractures in the first randomized clinical trial looking at the safety and efficacy of the technique specifically in patients with cancer.
Erlotinib Trumps Chemo in Advanced NSCLC With EGFR Mutations, Oct. 11, 2010. First-line erlotinib nearly tripled progression-free survival when compared with platinum-based chemotherapy in patients with advanced lung cancer carrying mutations activating the epidermal growth factor receptor.
Cetuximab Adds No Benefit to First-Line Regimen for Metastatic Colorectal Cancer, Oct. 11, 2010. Cetuximab in combination with a continuous or intermittently administered Nordic FLOX regimen for the first-line treatment of metastatic colorectal cancer conferred no advantage over the chemotherapy regimen alone, the first results of the Nordic VII study show.
PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival, Oct. 11, 2010. Final results from an open-label phase II study confirm the survival advantage of adding an investigational PARP inhibitor to gemcitabine and carboplatin chemotherapy in metastatic triple-negative breast cancer.
Early Results Favor Trastuzumab-DM1 in Randomized Breast Cancer Trial, Oct. 8, 2010. Trastuzumab-DM1 produced higher response rates with less toxicity than did a combination of trastuzumab and docetaxel in the first randomized trial of the novel agent as first-line therapy for metastatic HER2-positive breast cancer.